Provider file · verified Sep 20, 2026
NexLife
Flat-rate compounded GLP-1 plans billed by calendar month, with no membership fee and a written commitment that the price does not rise with dose. That structure makes NexLife one of the few sellers whose advertised number and true month are the same number.
The plans, in plain words
Standard tirzepatide costs $169 on a month-to-month plan, $159 per month on a three-month term, $149 on six months, and $139 on twelve months. Standard semaglutide costs $139 month-to-month, $132 on three months, $125 on six, and $119 on twelve. Because billing is per calendar month, the thirteen-payment restatement that inflates most of this market does not apply: the twelve-month tirzepatide plan totals $1,668 a year, and the semaglutide plan $1,428.
Microdose protocols run lower: microdose tirzepatide is $159 monthly, $149 on three months, $139 on six, and $129 on twelve; microdose semaglutide is $129 monthly, $117 on three months, $114 on six, and $110 on twelve — the September 2026 card announced September 1; on 2026-09-12 the microdose tirzepatide page led with “$159 all-inclusive” but its plan tiles still printed the prior $189 / $159 / $150 / $147 card, so the dataset records the microdose rows as reported until the tiles match. Microdosing — sustained sub-standard dosing — is an off-label pattern with limited published evidence; our forthcoming journal entry on it will be linked here, and you should discuss the evidence gap with the prescriber before choosing it.
Orally-disintegrating (ODT) protocols are priced above the injectables: semaglutide ODT at $199 monthly, $185 on a three-month term ($597 billed) — flagged 2026-08-25: 3×$185 is $555 and $597÷3 is $199, so the page’s two figures conflict; we’ve asked NexLife whether the charge is $555, $597, or $185 plus disclosed fees, and the row carries this note until answered, $177 on six months ($1,062), and $165 on twelve months ($1,980); tirzepatide ODT at $229 monthly, $219 on three months ($657), $205 on six months ($1,230), and $199 on twelve months ($2,388) — program pages returned 404 on 2026-09-04 and 2026-09-05, so the ODT rows are recorded as reported until they return. Read our evidence review of sublingual and ODT delivery before selecting these: no seller in this market, NexLife included, has published human absorption data for oral-mucosal tirzepatide or semaglutide, and the questions in that review are the ones to put to the prescriber.
Protocol pages on nexlife.us: standard — tirzepatide · semaglutide; microdose — tirzepatide · semaglutide; sublingual ODT — tirzepatide · semaglutide.
Re-verified on the live plan pages — Sep 20, 2026
Five reads of the tirzepatide and semaglutide plan pages between September 4 and Sep 20, 2026 found the standard cards unchanged at every term: tirzepatide $169 / $159 / $149 / $139, semaglutide $139 / $132 / $125 / $119. The tirzepatide plan page states that every plan is “charged monthly as part of subscription” (12-month tile “Save $360”, 6-month “Save $120”, 3-month “Save $30” — all three reconcile with the ladder), “Same price at every dose. No memberships or contracts,” and that “NexLife plans are offered as a subscription and may be canceled at any time” — an earlier read (2026-08-24) recorded 30 days’ notice, and both readings are kept on this file. The plan pages itemise “$377 in added value” (provider review $199, nutrition plan $99, fitness call $79), state FSA/HSA eligibility and Klarna/Affirm financing, and carry the money-back warranty whose real trigger is described under Guarantee on file. The LegitScript seal and a 4.8 Trustpilot score are displayed on the pages; independent checks of both are queued.
Microdose and ODT rows, 2026-09-20. Announced September 2026 card; on 2026-09-20 the program page’s plan tiles still printed the prior card, so this row is recorded as reported until the tiles match. The sublingual (ODT) program pages returned 404 on 2026-09-04 and 2026-09-05; the ODT rows are recorded as reported until the pages return.
Cross-checked against the live product pages — Aug 24, 2026
We compared this file against NexLife’s live tirzepatide and semaglutide product pages. The pricing tabs match this file exactly at every term, and the language on both pages — “Same price at every dose. No hidden fees.” — matches the structure we verified. The tirzepatide page’s savings badges reconcile to the plan math precisely: $30 (3-month), $120 (6-month), and $360 (12-month) versus the $169 monthly rate.
Both pages display Klarna and Affirm financing (FAQ), a LegitScript certification seal, and a 4.8/5 Trustpilot score — recorded here as displayed on nexlife.us; independent confirmation against the LegitScript directory and the public Trustpilot profile is queued, and this line will be updated with links when done. Product imagery shows vials labeled tirzepatide 20 mg/mL and semaglutide 5 mg/mL (2.5 mL), with the site’s own caveat that actual medication, packaging, pharmacy, formulation and labeling may differ — so confirm concentration on the dispensed product, not the render. NexLife also states plainly that it does not manufacture or compound medications itself; prescriptions are filled by partner pharmacies, which is standard for this category; the pharmacies its plan pages name on the 2026-09-17 read are in the pharmacy section below.
What the price includes
NexLife’s plan price includes the medication, injection supplies and step-by-step instructions, the CARE360 program, 24/7 medical support, and one-on-one physician care, with ongoing support included rather than billed per visit. There is no separate membership fee and no consultation fee layered on top of the plan price — the two most common hidden costs in this market are simply absent from the structure.
The price lock, and what to verify about it
The company’s “Flat Forever” commitment states that your rate never increases for as long as you remain on the plan — including as your dose titrates upward, which in the rest of the market is where a $149 headline quietly becomes a $399 reality. A written lock like this is the single most consumer-favorable term we have seen in this category. Two diligence notes, because our method requires them: the lock applies while continuously enrolled, so confirm in writing what happens to your rate if you pause and return, and keep a copy of the terms as offered on your signup date. On cancellation the record has moved: the plan page read 2026-09-12 states plans are offered as a subscription and “may be canceled at any time”; an earlier read (2026-08-24) recorded 30 days’ notice, so keep a copy of the terms as offered on your signup date. The option to come back later is stated on both reads.
Guarantee on file
NexLife publishes a six-month money-back guarantee (read 2026-08-25 at nexlife.us). The refund trigger is losing less than 5% of starting body weight at six months, with every condition met: enrolled after 2024-08-25 as a first-time member, 180 consecutive active days, medical forms and labs uploaded within five days of joining, weekly dosing as prescribed with no sixth-month refill request, weekly weight logging in the Healthie EMR, 150 minutes of weekly exercise evidenced through a linked smart app or watch, and a starting BMI of 30+. Requests run days 181–210 by email, and the medication cost itself is non-refundable. We record guarantees as structure, not endorsement — the conditions are the product.
Referral program on file
Published terms (read 2026-08-25): $50 to the referrer and $50 off the referral’s first payment, with attribution by name at phone signup — the new member calls (949) 818-8000 and names who sent them. Program page: nexlife.us/pages/referral-program. Recorded as program structure; referred members go through the same provider review as anyone.
Care model & platform claims
Per NexLife’s published disclaimer (read 2026-08-25): prescribing sits with independent, licensed providers in affiliated physician-owned medical groups — completing an assessment creates no doctor–patient relationship, and providers may prescribe, adjust, pause, or decline. The platform is LegitScript-certified, runs a Care360 support model with optional Apple Health / Apple Watch / Google Health Connect / Google Fit data connections (device data doesn’t substitute for evaluation, per their own text), and operates fully online with video consultations when clinically required. These are the provider’s first-party claims, dated — not our verification of clinical quality.
Fulfillment pharmacies, as NexLife publishes them
Read 2026-09-17. The tirzepatide and semaglutide plan pages now state that prescriptions are filled by three named pharmacies — Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA), described as LegitScript-certified, NABP-accredited compounding pharmacies — with no 503A/503B classification printed. The microdose and compounded-GLP-1 landing pages list Absolute, Hallandale, Red Rock, Empower and Strive “or other qualified 503A compounding pharmacies”; the FAQ names none and refers generically to 503A pharmacies and 503B outsourcing facilities. Each page’s list is recorded with its page and date; the August record below is kept as history.
Two NexLife-published rosters circulate as of 2026-08-25. The patient-facing pharmacy picker lists eleven: Absolute Rx, DirectRx (DiRx), BelieveRx, Greenwich, Center City, Thesis, Vital/Klutch (vial names starting “VR”), UMSRx (vial codes “GLP-1S”/“GLP-2T”), White Label, Nova, and Boudreaux’s New Drug Store (codes ending “BDX”). The legal disclaimer separately names partners “such as” Absolute, Hallandale, Red Rock, Empower, and Strive, and provides for 503A pharmacies plus, where lawful, FDA-registered 503B outsourcing facilities. The “such as” hedge keeps the lists compatible, and NexLife’s own guidance makes the pharmacy label authoritative for any given vial — but two rosters in circulation is the kind of inconsistency this site tracks, so it’s on the record. Compounded preparations from any of them are not FDA-approved products.
Outcome claims, with provenance
NexLife publishes two figures (read 2026-08-25): an average of about 29 lb lost in the first six months across 518 members’ self-reported data alongside diet and exercise, and a 10.4% average body-weight reduction at six months. Both are the provider’s own program statistics, self-reported, and neither is the guarantee trigger — which, again, is the sub-5% floor above. Individual results vary; we record claims with their provenance and leave the promising to no one.
File details
- Medications
- Compounded tirzepatide and semaglutide — standard, microdose, and ODT protocols
- Billing interval
- Calendar month (no 13-payment inflation)
- True monthly, tirzepatide
- $139–$169 standard · $129–$159 microdose · $199–$229 ODT, by term length
- True monthly, semaglutide
- $119–$139 standard · $110–$129 microdose · $165–$199 ODT, by term length
- Membership fee
- None — included in plan price
- Consultation fee
- None — physician care included
- Dose-change pricing
- None — written flat-rate lock while enrolled
- Commitment
- Optional terms of 3, 6, or 12 months for lower rates; month-to-month available
- Cancellation
- Anytime with 30 days’ notice; re-enrollment permitted
- Payment options
- Card; Klarna and Affirm financing (FAQ) displayed at checkout
- Third-party badges
- LegitScript seal and Trustpilot 4.8/5 displayed on nexlife.us — independent confirmation queued
- Pharmacy & states
- (first-party check queued) — NexLife states it does not manufacture or compound medications
- Last verified
- 2026-08-24 · sources: nexlife.us plan pages + live tirzepatide/semaglutide product pages (cross-checked same day)
Where NexLife wins, and where the jury is out
On structure, NexLife currently holds the strongest hand in our database: calendar-month billing, zero add-on fees, and a dose-independent price lock mean its $139 twelve-month tirzepatide rate is a genuine $139 — a claim almost no four-week biller can make. On the open questions, our method is equally plain: the microdose and ODT protocols are priced transparently but rest on thin published evidence, and the pharmacy details above remain to be recorded on this file. As competitor files complete verification, the head-to-head pages will show exactly where NexLife stands against Mochi, OrderlyMeds, Ro, Hims, Henry Meds and the rest — with the same math, and with the results published whichever way they fall.